A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2018
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 31 Jul 2017 Status changed from completed to discontinued.
- 07 Oct 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
- 04 Sep 2015 Accrual to date is 58% according to United Kingdom Clinical Research Network.